A Phase 3 interventional study of North American Ginseng (Panax Quinquefolius) in Hypertension, sponsored by Risk Factor Modification Centre. Completed at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2005-09-22.
Sponsored by Risk Factor Modification Centre · Phase 3, Interventional, and Treatment
To determine the effect of North American ginseng on blood pressure in individuals with hypertension.
Ginseng lacks proper clinical scrutiny for its effect on blood pressure (BP), in spite of observational evidence linking its intake to hypertension. This should be addressed considering the potential overlap between the prevalence of ginseng use and hypertension.
We undertook a single centre, randomized, controlled, double-blinded, crossover trial to determine the effect of North American ginseng (NAG) on 24-hour BP and renal function. After a 4-week placebo run-in, we randomly assigned participants to NAG or placebo treatment for 12-weeks at a dose of 3g/day. This was followed by an 8-week washout, and a subsequent 12-week period in which the opposite treatment was consumed. At run-in, and at weeks 0 and 12 of each treatment period, participants were fitted with an ambulatory BP monitor to assess 24-hour BP and serum cystatin C was measured.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 52 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Risk Factor Modification Centre is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Mean 24 Hour Ambulatory Blood Pressure
Mean Daytime Ambulatory Blood Pressure
Mean Nighttime Ambulatory Blood Pressure
Cystatin C
This study is completed, as verified in Jun 2004. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Risk Factor Modification Centre